001431246 000__ 04871cam\a2200673Ii\4500
001431246 001__ 1431246
001431246 003__ OCoLC
001431246 005__ 20230308003227.0
001431246 006__ m\\\\\o\\d\\\\\\\\
001431246 007__ cr\un\nnnunnun
001431246 008__ 220107s2022\\\\sz\\\\\\ob\\\\001\0\eng\d
001431246 019__ $$a1294352268$$a1294393713
001431246 020__ $$a9783030891251$$q(electronic bk.)
001431246 020__ $$a3030891259$$q(electronic bk.)
001431246 020__ $$z9783030891244$$q(print)
001431246 0247_ $$a10.1007/978-3-030-89125-1$$2doi
001431246 035__ $$aSP(OCoLC)1291278076
001431246 040__ $$aGW5XE$$beng$$erda$$epn$$cGW5XE$$dOCLCO$$dDCT$$dOCLCF$$dOCLCO$$dOCLCQ
001431246 0411_ $$aeng$$hfre
001431246 049__ $$aISEA
001431246 050_4 $$aRA644.C67
001431246 08204 $$a362.1962/414$$223
001431246 1001_ $$aVelásquez, Germán,$$d1948-$$eauthor.
001431246 24010 $$aVaccins, médicaments et brevets.$$lEnglish
001431246 24510 $$aVaccines, medicines and COVID-19 :$$bhow can WHO be given a stronger voice? /$$cGermán Velásquez.
001431246 264_1 $$aCham, Switzerland :$$bSpringer,$$c2022.
001431246 300__ $$a1 online resource (xvi, 117 pages)
001431246 336__ $$atext$$btxt$$2rdacontent
001431246 337__ $$acomputer$$bc$$2rdamedia
001431246 338__ $$aonline resource$$bcr$$2rdacarrier
001431246 347__ $$atext file$$bPDF$$2rda
001431246 4901_ $$aSpringerBriefs in public health,$$x2192-3701
001431246 504__ $$aIncludes bibliographical references and index.
001431246 5050_ $$aChapter 1: COVID-19 Vaccines: Between Ethics, Health and Economics -- Chapter 2: Medicines and Intellectual Property: 10 Years of the WHO Global Strategy -- Chapter 3: Re-thinking Global and Local Manufacturing of Medical Products After COVID-19 -- Chapter 4: Rethinking R&D for Pharmaceutical Products After the Novel Coronavirus COVID-19 Shock -- Chapter 5: Intellectual Property and Access to Medicines and Vaccines -- Chapter 6: The World Health Organization Reforms in the Time of COVID-19 -- Epilogue.
001431246 5060_ $$aOpen access.$$5GW5XE
001431246 520__ $$aThis open access book is a collection of research papers on COVID-19 by Germán Velásquez from 2020 and early 2021 that help to answer the question: How can an agency like the World Health Organization (WHO) be given a stronger voice to exercise authority and leadership? The considerable health, economic and social challenges that the world faced at the beginning of 2020 with COVID-19 continued and worsened in many parts of the world in the second-half of 2020 and into 2021. Many of these countries and nations wanted to explore COVID-19 on their own, sometimes without listening to the main international health bodies such as WHO, an agency of the United Nations system with long-standing experience and vast knowledge at the global level and of which all countries in the world are members. In this single volume, the chapters present the progress of thinking and debate -- particularly in relation to drugs and vaccines -- that would enable a response to the COVID-19 pandemic or to subsequent crises that may arise. Among the topics covered: COVID-19 Vaccines: Between Ethics, Health and Economics Medicines and Intellectual Property: 10 Years of the WHO Global Strategy Re-thinking Global and Local Manufacturing of Medical Products After COVID-19 Rethinking R&D for Pharmaceutical Products After the Novel Coronavirus COVID-19 Shock Intellectual Property and Access to Medicines and Vaccines The World Health Organization Reforms in the Time of COVID-19 Vaccines, Medicines and COVID-19: How Can WHO Be Given a Stronger Voice? is essential reading for negotiators from the 194 member countries of the World Health Organization (WHO); World Trade Organization (WTO) and World Intellectual Property Organization (WIPO) staff participating in these negotiations; academics and students of public health, medicine, health sciences, law, sociology and political science; and intergovernmental organizations and non-governmental organizations that follow the issue of access to treatments and vaccines for COVID-19.
001431246 588__ $$aOnline resource; title from PDF title page (SpringerLink, viewed January 7, 2022).
001431246 61020 $$aWorld Health Organization.
001431246 647_7 $$aCOVID-19 Pandemic$$d(2020-)$$2fast$$0(OCoLC)fst02024716
001431246 650_0 $$aCOVID-19 Pandemic, 2020-
001431246 650_0 $$aVaccines.
001431246 650_0 $$aCOVID-19 (Disease)
001431246 650_0 $$aCOVID-19 (Disease)$$xPolitical aspects.
001431246 650_0 $$aCOVID-19 (Disease)$$xSocial aspects.
001431246 650_6 $$aPandémie de COVID-19, 2020-
001431246 650_6 $$aVaccins.
001431246 650_6 $$aCOVID-19.
001431246 650_6 $$aCOVID-19$$xAspect politique.
001431246 650_6 $$aCOVID-19$$xAspect social.
001431246 655_0 $$aElectronic books.
001431246 77608 $$iPrint version: $$z9783030891244
001431246 77608 $$iPrint version: $$z9783030891268
001431246 830_0 $$aSpringerBriefs in public health,$$x2192-3701
001431246 852__ $$bebk
001431246 85640 $$3Springer Nature$$uhttps://link.springer.com/10.1007/978-3-030-89125-1$$zOnline Access$$91397441.2
001431246 909CO $$ooai:library.usi.edu:1431246$$pGLOBAL_SET
001431246 980__ $$aBIB
001431246 980__ $$aEBOOK
001431246 982__ $$aEbook
001431246 983__ $$aOnline
001431246 994__ $$a92$$bISE